


# Protective Role of H<sub>2</sub>S in High Glucose-Induced Cardiomyocyte and Endothelial Cell Dysfunction: A Mechanistic Review

Xiaoya Zhai<sup>1,\*</sup>, Yefei Gao<sup>1,\*</sup>, Haifei Lou<sup>1</sup>, Liping Meng<sup>1</sup>, Jiedong Zhou<sup>2</sup>, Hui Lin<sup>3</sup>, Fukang Xu<sup>1</sup>

<sup>1</sup>Department of Cardiology, Shaoxing People's Hospital, Shaoxing, People's Republic of China; <sup>2</sup>Cardiovascular Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315211, People's Republic of China; <sup>3</sup>Department of Cardiology, The Affiliated Lihuli Hospital of Ningbo University Health Science Center, Ningbo, Zhejiang, 315211, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Hui Lin; Fukang Xu, Email 122525790@qq.com; xufukang810302@163.com

**Abstract:** Hydrogen sulfide (H<sub>2</sub>S), recognized as a significant gasotransmitter, has been shown to effectively reduce damage to cardiomyocytes and endothelial cells caused by diabetes. Its protective effects primarily stem from several mechanisms, including S-sulfhydration of proteins, reduction of cell death, alleviation of mitochondrial damage, improvement of ion channel dysfunction, interaction with nitric oxide, and modulation of angiogenesis. H<sub>2</sub>S is synthesized by cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST), whose expression is significantly reduced under diabetic conditions, including experimental high-glucose treatment in cells and diabetes mellitus animal models. This review summarizes the protective role of H<sub>2</sub>S and its donors in these pathological processes, highlights existing research gaps—including challenges in the targeted delivery of H<sub>2</sub>S donors, limited clinical translation, and incomplete mechanistic understanding—and discusses future directions for developing targeted H<sub>2</sub>S-based therapeutic strategies.

**Keywords:** H<sub>2</sub>S, diabetic cardiomyopathy, diabetes-induced endothelial cell damage

## Introduction

Hydrogen sulfide (H<sub>2</sub>S) is a colorless gas characterized by its toxicity, corrosiveness, and flammability, and is prevalent in both environmental and industrial pollutants.<sup>1,2</sup> Recent research has demonstrated that H<sub>2</sub>S is integral to cellular signal transduction and the regulation of various biological activities.<sup>3–5</sup> As one of the three recognized gaseous signaling molecules, H<sub>2</sub>S significantly influences cardiovascular function, alongside carbon monoxide (CO) and nitric oxide (NO). Hydrogen sulfide (H<sub>2</sub>S) is a colorless gas with toxicity and flammability, commonly found in environmental and industrial pollutants. Recent studies have shown that H<sub>2</sub>S plays a vital role in cellular signaling and regulation of various biological processes, particularly in cardiovascular function, alongside carbon monoxide (CO) and nitric oxide (NO). H<sub>2</sub>S is a weak acid that, when dissolved in water, mainly exists as hydrogen sulfide ions (HS<sup>−</sup>) at physiological pH. These highly reactive ions interact with various cellular targets, influencing a range of physiological and pathophysiological processes.<sup>6–9</sup> Researchers are actively investigating small molecule donors for the exogenous delivery and bioavailability of H<sub>2</sub>S, driven by its potential as a cardioprotective agent.<sup>10–12</sup> These attributes highlight the critical role of H<sub>2</sub>S and its promising applications in physiological and pathophysiological processes, especially within the cardiovascular system.

Diabetes, an endocrine disorder characterized by elevated blood glucose levels, is one of the most common and rapidly escalating conditions globally.<sup>13,14</sup> Studies have demonstrated that diabetes serves as an independent risk factor for patients with heart failure, contributing to cardiac hypertrophy as well as both systolic and diastolic dysfunction.<sup>15,16</sup> Diabetes not only disrupts blood glucose regulation but also significantly impairs vascular endothelial function and cardiac health, contributing to complications such as diabetic nephropathy, diabetic foot, diabetic retinopathy, and diabetic cardiomyopathy.<sup>17–19</sup>


Despite emerging evidence supporting the cardioprotective and vasoprotective effects of H<sub>2</sub>S, its precise molecular mechanisms in mitigating diabetes-induced cardiovascular damage remain insufficiently understood. Current studies focus mainly on its general regulatory roles, but further investigation is needed to clarify how H<sub>2</sub>S specifically interacts with key pathological pathways in diabetic cardiomyopathy and vascular complications. This review aims to summarize existing knowledge, identify research gaps, and explore the therapeutic mechanisms of H<sub>2</sub>S in diabetes-induced myocardial and endothelial cell damage, providing insights into potential clinical applications and novel intervention strategies.

## The Production of Endogenous H<sub>2</sub>S

In mammalian cells, H<sub>2</sub>S is endogenously produced via both enzymatic and non-enzymatic pathways. Research has identified enzymatic catalysis as the predominant production mechanism, with cystathionine β-synthase (CBS),<sup>20</sup> cystathionine γ-lyase (CSE),<sup>21</sup> and 3-mercaptopyruvate sulfurtransferase (3-MST)<sup>22</sup> being the principal enzymes involved in this process.<sup>23,24</sup> CBS and CSE utilize pyridoxal phosphate (vitamin B6) as a cofactor, with CBS predominantly expressed in the central nervous system and liver,<sup>25</sup> while CSE regulates H<sub>2</sub>S levels in the cardiovascular and respiratory systems.<sup>26,27</sup> These enzymes catalyze the conversion of homocysteine to cysteine via the reverse transsulfuration pathway, resulting in the production of H<sub>2</sub>S. Meanwhile, 3-MST, requiring zinc, works in mitochondria alongside cysteine aminotransferase (CAT) to generate H<sub>2</sub>S.<sup>28</sup> In addition to enzymatic pathways, non-enzymatic mechanisms involving L-cysteine under the action of CAT produce 3-mercaptoacetate (3-MP). This compound, when co-catalyzed by CAT in mitochondria, leads to the generation of H<sub>2</sub>S and pyruvic acid. In studies on high glucose conditions, CSE is the most commonly assessed marker of H<sub>2</sub>S production due to its predominant expression in the cardiovascular system and its significant downregulation under hyperglycemia.<sup>29,30</sup> In contrast, CBS and 3-MST are less frequently measured, as their expression in the cardiovascular system is lower and their changes under high glucose conditions are less consistent<sup>29</sup> (Figure 1).

## The Metabolism of Endogenous H<sub>2</sub>S

H<sub>2</sub>S is eliminated from the body through various routes: as gaseous molecules via the respiratory tract,<sup>31</sup> as thiosulfates or free sulfates in urine,<sup>32</sup> and as free sulfides in feces through the digestive tract.<sup>33</sup> Primarily, H<sub>2</sub>S undergoes metabolism via three main pathways, with the mitochondrial sulfur oxidation pathway being particularly significant for H<sub>2</sub>S clearance. In this pathway, sulfur compound quinone oxidoreductase plays a crucial role by catalyzing the oxidation




**Figure 1** Diagram of H<sub>2</sub>S Production Pathways. H<sub>2</sub>S is produced through three main enzymatic pathways: the CBS (cystathionine β-synthase) pathway, the CSE (cystathionine γ-lyase) pathway, and the 3-MST (3-mercaptopyruvate sulfurtransferase) pathway. In the CBS pathway, homocysteine is converted to cystathionine and then to L-cysteine, which is further metabolized to generate H<sub>2</sub>S. The CSE pathway directly converts L-cysteine into pyruvate while releasing H<sub>2</sub>S. In the 3-MST pathway, L-cysteine is first converted into 3-mercaptopyruvate by cysteine aminotransferase (CAT), which is then metabolized by 3-MST to produce H<sub>2</sub>S. These pathways collectively regulate endogenous H<sub>2</sub>S levels.

of H<sub>2</sub>S to thiosulfate. Additionally, other mechanisms, including methemoglobin, metal-containing macromolecules, and sulfur-containing macromolecules, contribute to the clearance of H<sub>2</sub>S.<sup>34,35</sup> Methyhemoglobin and myoglobin enhance the binding of hydrogen sulfide to iron, consequently accelerating its oxidation rate by altering iron reactivity.<sup>36</sup> Furthermore, H<sub>2</sub>S could undergo metabolism via methylation processes involving glutathione, glycine disulfide, or other molecules containing metals or disulfide bonds.<sup>37</sup>

## H<sub>2</sub>S S-Sulfidation

S-sulfide hydration denotes the process by which H<sub>2</sub>S molecules interact with or modify cysteine residues within proteins. This post-translational modification can significantly impact protein function and stability, thereby playing a crucial role in the regulation of vital biological activities, including intracellular signaling, metabolic pathways, and the pathogenesis of various diseases. Emerging research suggests that H<sub>2</sub>S is implicated in protein sulfhydration through these interactions and has the potential to ameliorate myocardial cell damage induced by high glucose (HG) conditions. Sun's study has demonstrated that H<sub>2</sub>S can mitigate the inhibition of the interaction between Myosin Heavy Chain 6 (MYH6) and Myosin Light Chain 2 (MyL2) by Muscle-Specific RING Finger Protein 1 (MuRF1) through S-sulfhydration at the Cys44 site of MuRF1. This process consequently reduces the ubiquitination levels of MYH6 and MyL2, thereby alleviating HG-induced myocardial degeneration and damage.<sup>38</sup> Additionally, further investigations have examined the relationship between H<sub>2</sub>S and the sulfhydration of ubiquitin-specific protease 8 (USP8). These studies revealed that under conditions of elevated glucose and fat levels, USP8 sulfhydration significantly decreases; however, its expression is notably upregulated following the administration of exogenous H<sub>2</sub>S. S-sulfide hydration of USP8 enhances parkin deubiquitination, boosting mitochondrial autophagy in myocardial cells, reducing mitochondrial damage, and improving diabetic cardiomyopathy.<sup>29</sup> Yu's research shows that exogenous H<sub>2</sub>S S-sulfhydrates Synovial Apoptosis Inhibitor 1 (Hrd1) at the Cys115 site, lowering VAMP3 ubiquitination and CD36 translocation, which decreases long-chain fatty acid uptake and alleviates diabetic cardiomyopathy.<sup>39</sup> Similarly, Sun et al reported that H<sub>2</sub>S enhances the S-sulfhydration levels at the Cys115 site on Hrd1. However, their findings also indicated that Hrd1 inhibits the interaction between Hrd1 and Diacylglycerol O-Acyltransferase 1 (DGAT1) as well as Diacylglycerol O-Acyltransferase 2 (DGAT2) by modulating the ubiquitination levels of DGAT1 and DGAT2. This regulatory mechanism reduces the formation and uptake of lipid droplets in myocardial cells, thereby mitigating diabetic cardiomyopathy.<sup>40</sup> Additionally, Peng's research demonstrates that exogenous H<sub>2</sub>S promotes S-sulfhydration at the Cys683 site of SUMO-specific protease 1 (SEN1), leading to enhanced Sumoylation of the ATPase Sarcoplasmic/Endoplasmic Reticulum Ca<sup>2+</sup> Transporter 2 (SERCA2A). SERCA2A is crucial for calcium reuptake into the endoplasmic reticulum during excitation-contraction coupling in cardiac cells, which improves cardiac contraction-relaxation function and reduces apoptosis in diabetic cardiomyopathy.<sup>30</sup> Zhang et al discovered that exogenous H<sub>2</sub>S increases S-sulfhydration of SYVN1 at the Cys115 site, upregulating the ubiquitination of Sterol Regulatory Element-Binding Protein 1 (SREBP1) and downregulating the expression of DGAT1 and 1-Acylglycerol-3-Phosphate O-Acyltransferase 3 (AGPAT3), both key factors in lipid droplet formation, thereby contributing to reduced lipid accumulation.<sup>41</sup> In Wang's study, H<sub>2</sub>S-mediated S-sulfhydration of SYVN1 was found to be associated not only with lipid droplet accumulation but also with the regulation of ferroptosis and mitochondrial apoptosis.<sup>42</sup> Specifically, H<sub>2</sub>S enhances S-sulfhydration of SYVN1 at the Cys115 site, increasing the ubiquitination of Kelch-like ECH-associated protein 1 (Keap1), which promotes the nuclear translocation of NFE2-like BZIP transcription factor 2 (Nrf2), thereby modulating ferroptosis and apoptosis in diabetic cardiomyopathy.<sup>43</sup> Thus, in diabetic cardiomyopathy, H<sub>2</sub>S-mediated S-sulfhydration regulates various target functions and signaling pathways by affecting specific sites on proteins such as MuRF1, USP8, Hrd1, SERCA2A, and SYVN1. However, there is limited research investigating the protective mechanisms of H<sub>2</sub>S against HG-induced endothelial cell damage through sulfide hydration. The study by Xie et al demonstrated that H<sub>2</sub>S enhances Keap1 sulfide hydration, which promotes the mercaptanization of Keap1 at cysteine residue 151. This modification leads to the dissociation of Nrf2 from Keap1, facilitating the nuclear translocation of Nrf2 and reducing oxidative stress, thereby mitigating HG-induced atherosclerosis.<sup>44</sup> We have summarized the relevant mechanisms and illustrated them in a schematic diagram to provide a clear visualization of how H<sub>2</sub>S-mediated S-sulfhydration functions in diabetic cardiomyopathy and HG-induced endothelial cell damage, as shown in [Figure 2](#).




**Figure 2** H<sub>2</sub>S improves the damage to cardiomyocytes and endothelial cells induced by HG through S-sulfidation.

**Abbreviations:** MuRF1, Muscle-Specific RING Finger Protein 1; USP8, Ubiquitin-Specific Protease 8; Hrd1, Synovial Apoptosis Inhibitor 1; SENP1, SUMO-specific protease 1; Keap1, Kelch-like ECH-associated protein 1.

## H<sub>2</sub>S Attenuates HG Induced Mitochondrial Damage in Cells

Mitochondria, the most prevalent organelles in cardiomyocytes and endothelial cells, play a crucial role in energy provision for daily physiological activities.<sup>45,46</sup> However, elevated glucose levels can impair mitochondrial function, metabolism, and quality control mechanisms.<sup>45–47</sup> HG exposure has been shown to alter mitochondrial morphology and upregulate caspase-3, caspase-9, mitochondrial NADPH oxidase 4 (NOX4), and cytochrome c expression, contributing to mitochondrial dysfunction.<sup>48</sup> Yang et al demonstrated that H<sub>2</sub>S mitigates HG-induced mitochondrial damage by down-regulating Mitofusin 2 (Mfn2), a key regulator of mitochondrial dynamics.<sup>49</sup> Additionally, H<sub>2</sub>S enhances mitochondrial respiratory chain activity and ATP production by restoring NAD levels, upregulating SIRT3, and reducing acetylation of key mitochondrial enzymes such as NADH ubiquinone oxidoreductase, ubiquinol-cytochrome C reductase, and ATP synthase. These mechanisms collectively improve mitochondrial function and energy metabolism.<sup>50</sup> Further studies suggest that H<sub>2</sub>S may influence mitochondrial processes, including autophagy, fusion, and fission, which help restore mitochondrial function in cardiomyocytes. Exogenous H<sub>2</sub>S has been shown to activate the parkin signaling pathway, increasing the expression of the mitochondrial fusion protein Mfn2 and the fission proteins Fission, Mitochondrial 1 (Fis1) and Dynamin 1 Like (DRP1), thereby promoting mitochondrial autophagy.<sup>29</sup>

Other studies have similarly demonstrated that H<sub>2</sub>S ameliorates endothelial cell function by mitigating mitochondrial damage. It inhibits mitochondrial fragmentation and suppresses phosphorylated DRP1 and Fis1 expression, thereby maintaining mitochondrial integrity. Immunoprecipitation and immunostaining analyses further reveal that H<sub>2</sub>S facilitates the recruitment of PTEN-induced putative kinase 1 to Parkin, leading to ubiquitination and degradation of Mfn2, ultimately enhancing mitochondrial autophagy.<sup>51</sup> Furthermore, targeting mitochondrial dysfunction with H<sub>2</sub>S donors, such as AP39 and AP123, effectively counteracts oxidative stress. These compounds mitigate mitochondrial membrane hyperpolarization, suppress mitochondrial ROS production, and enhance electron transfer at respiratory complex III, thereby improving endothelial cell metabolism.<sup>52</sup> Notably, under hyperglycemic conditions, the generation of mitochondrial reactive oxygen species (ROS) and the enhanced catabolism of H<sub>2</sub>S establish a positive feed-forward loop.<sup>53</sup> We have summarized the mechanisms by which H<sub>2</sub>S alleviates high glucose-induced mitochondrial damage in cardiomyocytes and endothelial cells in a schematic diagram, as shown in Figure 3.



**Figure 3** H<sub>2</sub>S attenuates HG induced mitochondrial damage in both cardiomyocytes and endothelial cells.

**Abbreviations:** NAD, Nicotinamide Adenine Dinucleotide; Sirt3, Sirtuin 3; PINK1, PTEN Induced Kinase 1; Parkin, Parkin RBR E3 Ubiquitin Protein Ligase.

## H<sub>2</sub>S Improves HG Induced Ion Channel Disorders

Beyond its mitochondrial protective role, H<sub>2</sub>S also regulates cellular homeostasis by modulating ion channels, which are key to cellular excitability and ion transport. Under hyperglycemia, ion channel dysfunction contributes to oxidative stress and apoptosis. By restoring ion channel function, H<sub>2</sub>S helps maintain cardiomyocyte and endothelial integrity, offering broader protection in diabetic complications. Although there is a substantial body of literature addressing the impact of H<sub>2</sub>S in various myocardial injury models, Testai et al demonstrated that the H<sub>2</sub>S donor Erucin protects the heart from ischemia-reperfusion injury by targeting mitoKv7.4 channels. Their findings revealed that Erucin exerts its cardioprotective effects through the persulfidation of mitoKv7.4, identifying this channel as a novel mitochondrial K<sup>+</sup> channel involved in cardioprotection.<sup>54</sup> Wu et al discovered that CSE-derived H<sub>2</sub>S regulates cardiac function by modulating Drp1 activity through S-sulphydration at cysteine 607, thereby affecting its interaction with voltage-dependent anion channel 1 (VDAC1). This mechanism plays a crucial role in protecting against heart failure.<sup>55</sup> H<sub>2</sub>S improves myocardial infarction outcomes by inhibiting I<sub>to</sub> channels through direct modification of the Kv4.2 subunit at the Cys320/Cys529 disulfide bond. This regulation reduces the risk of fatal ventricular arrhythmias., research focusing on diabetic cardiomyopathy models remains limited. Liang et al demonstrated that HG conditions significantly reduce the expression levels of ATP-sensitive potassium (K<sub>ATP</sub>) channels in cardiomyocytes. However, pre-treatment of cells with NaHS for 30 minutes effectively reverses this reduction, leading to an increase in K<sub>ATP</sub> channel expression and a concomitant decrease in cell apoptosis, oxidative stress, and mitochondrial damage. Interventions using diazoxide (a mitochondrial K<sub>ATP</sub> channel opener) or pinacidil (a non-selective K<sub>ATP</sub> channel opener) weaken the protective effect of NAHS on myocardial cells.<sup>56</sup> Researchers also explored the role of H<sub>2</sub>S in mitigating ion channel dysfunction in diabetic kidney endothelial cell injury. John et al suggest that under HG conditions, the activation of L-type Ca<sup>2+</sup> channels lead to intracellular Ca<sup>2+</sup> influx, which in turn activates cyclophilin D. This activation induces the opening of the mitochondrial permeability transition pore regulator, increasing oxidative stress and contributing to glomerular endothelial cell damage in diabetes. H<sub>2</sub>S, however, protects against diabetic kidney injury by blocking N-methyl-D-aspartic acid receptor (NMDA-R1)-mediated Ca<sup>2+</sup> influx.<sup>57</sup> Thus, by modulating ion channel activity, H<sub>2</sub>S exerts protective effects in both

diabetic cardiomyopathy and diabetic nephropathy endothelial cells, offering a promising therapeutic pathway for improving heart and kidney function.

## H<sub>2</sub>S Improves HG Induced Cell Death

Apoptosis is a programmed cell death process initiated intrinsically by the cell, proceeding in a spontaneous and orderly manner in response to specific signals or conditions.<sup>58–60</sup> This mechanism facilitates the organized and efficient removal of damaged cells. H<sub>2</sub>S has been shown to mitigate myocardial cell apoptosis through various pathways and mechanisms, including the endoplasmic reticulum stress<sup>61,62</sup> or mitochondrial damage<sup>63,64</sup> axis under HG conditions. Excessive endoplasmic reticulum stress causes the buildup of unfolded proteins, speeding up cell apoptosis.<sup>65</sup> Mitochondrial damage, influenced by changes in cytosolic calcium levels, redox status, and ROS, also triggers apoptosis by activating mitochondrial permeability transition pores.<sup>66</sup> Additionally, H<sub>2</sub>S has been shown to modulate several critical signaling pathways, including Nuclear Factor kappa-B (NF-κB), Keap1/NRF2, and Wnt/β-catenin, which are integral to antioxidative stress responses, anti-apoptotic mechanisms, and anti-inflammatory processes (Table 1). Furthermore, existing

**Table 1** H<sub>2</sub>S Improves HG Induced Cardiomyocyte Death

Donor	Model	Pathway	Implication
NaHS	STZ-induced DCM mouse HG-induced NRCM	Nrf2/ARE JNK/AMPK PI3K/Akt	Attenuate inflammation Oxidative stress and apoptosis <sup>69</sup>
NaHS	STZ-induced DCM mouse PA-induced AC16 cell	NA	Attenuate ER stress and apoptosis <sup>70</sup>
SPRC	STZ-induced DCM mouse HG-induced H9C2 cell	Keap1/Nrf2	Attenuate apoptosis <sup>71</sup>
NaHS	STZ-induced DCM mouse HG-induced NRCM	MAPK /ERK I	Protect mitochondria And attenuate apoptosis <sup>72</sup>
NaHS	HG-induced H9C2 cell	AMPK/NF-κB	Attenuate inflammation <sup>73</sup>
Diallyl trisulfide	STZ-induced DCM mouse HG-induced H9C2 cell	IGF1R/Akt	Attenuate apoptosis <sup>74</sup>
NaHS	STZ-induced DCM mouse HG-induced H9C2 cell	ROS/Mfn2	Attenuate ER stress And mitochondrial apoptosis <sup>49</sup>
NaHS	HG-induced H9C2 cell	TLR4/NF-κB	Attenuate inflammation and apoptosis <sup>75</sup>
NaHS	Db/db mice HG+Ole+PA-induced NRCM	USP8/parkin	Upregulated mitophagy <sup>29</sup>
NaHS	HG-induced H9C2 cell HG-induced NRCM	Wnt/β-catenin	Attenuate apoptosis <sup>76</sup>
NaHS	Db/db mice HG+Ole+PA-induced NRCM	SENPI/SERCA2a	Attenuate apoptosis <sup>30</sup>
NaHS	Db/db mice HG+PA-induced HL-1 cell	Syvn1/Nrf2/GPx4	Attenuate ferroptosis And mitochondrial apoptosis <sup>43</sup>
EXERCISE	HFD-induced DCM mouse	CSE/H <sub>2</sub> S	Attenuate pyroptosis <sup>77</sup>
NaHS	STZ-induced DCM mouse Db/db mice	CSE/NLRP3	Attenuate necroptosis And oxidative stress <sup>78</sup>
NaHS	HG-induced NRCM Sg/sf mice	E2F1/RORα/Stat3	Attenuate necroptosis <sup>79</sup>
NaHS	HG-induced H9C2 cell STZ-induced DCM rat	Sirt6/AMPK	Attenuate autophagy <sup>80</sup>
NaHS	Db/db mice HG+PA-induced H9C2 cell	Keap1/ROS	Attenuate autophagy <sup>81</sup>
NaHS	STZ-induced DCM rat HG-induced NRCM	ROS/NLRP3	Attenuate pyroptosis <sup>82</sup>

**Abbreviations:** NRCM, Neonatal Rat Cardiomyocyte; PA, Palmitic acid; Ole, Oleic acid; STZ, Streptozocin; S-Propargylcysteine.



literature indicates that H<sub>2</sub>S can regulate the expression of AMP-activated protein kinase (AMPK), a pivotal molecule in the regulation of cellular energy metabolism. AMPK functions as an energy sensor within cells, becoming activated under conditions of stress to facilitate metabolic reprogramming and maintain redox homeostasis.<sup>67</sup> AMPK is vital for diabetes research and cell apoptosis regulation, linked to HG-induced cardiomyocyte apoptosis.<sup>68</sup> These pathways have been shown in other studies to be associated with HG-induced cardiomyocyte apoptosis. H<sub>2</sub>S influences multiple signaling pathways, not just one, to regulate cardiomyocyte apoptosis.

Studies have shown that H<sub>2</sub>S can mitigate HG-induced myocardial cell damage by reducing other forms of cell death, including pyroptosis, ferroptosis, autophagy, and necroptosis. Liu et al discovered that H<sub>2</sub>S decreases pyroptosis via the ROS/ NLR Family Pyrin Domain Containing 3 (NLRP3) pathway by lowering HG-induced ROS, which in turn reduces NLRP3 inflammasome production, a key mediator of pyroptosis. Thus, inhibiting H<sub>2</sub>S can decrease ROS and NLRP3 levels, alleviating myocardial cell pyroptosis.<sup>82</sup> Wang et al found that H<sub>2</sub>S reduces ferroptosis in heart cells by enhancing Keap1 ubiquitination via Syvn1, promoting Nrf2 nuclear translocation, which regulates ferroptosis.<sup>43</sup> Additionally, Li et al showed that NaHS increases CSE protein expression, activating autophagy through the Sirt6/AMPK pathway, thereby preventing cardiac cell aging and countering HG toxicity. However, the protective effect of NaHS is reversed when a CSE inhibitor dl-propargylglycine is used.<sup>80</sup> H<sub>2</sub>S protects myocardial cells through autophagy by modulating Keap1. Specifically, H<sub>2</sub>S increases Keap1 expression by inhibiting its ubiquitination level, thereby enhancing the autophagic clearance of ubiquitin aggregates to protect the heart. 1,4-dithiothreitol, a disulfide bond inhibitor, can elevate the ubiquitination level of Keap1, reduce Keap1 expression, and diminish the effects of NaHS on the clearance of ubiquitin aggregates and ROS production in myocardial cells.<sup>81</sup> Studies have also indicated that necroptosis, a novel form of regulated necrotic cell death, contributes to the cardioprotective effects of H<sub>2</sub>S. Gong revealed that exogenous H<sub>2</sub>S supplementation alleviates necroptosis in diabetic cardiomyopathy by reducing mitochondrial damage, oxidative stress, and inhibiting NLRP3 inflammasome activation.<sup>78</sup> NaHS can increase the expression of E2F transcription factor 1 (E2F1), which subsequently promotes the transcription of RAR-related Orphan Receptor A (RORα) to alleviate necroptosis and oxidative stress, enhance mitochondrial membrane potential, and prevent diabetic cardiomyopathy.<sup>79</sup> We have summarized the relevant findings in Table 1 to provide a clearer and more direct visualization of the target mechanisms of H<sub>2</sub>S.

H<sub>2</sub>S mitigates HG-induced endothelial cell death, primarily through apoptosis and necroptosis, similar to its effects on cardiomyocytes.<sup>83</sup> Zhou suggested that the H<sub>2</sub>S donor AP123 enhances cAMP response element-binding protein (CREB) via the Phosphoinositide 3-kinase (PI3K) pathway, regulating endothelial Nitric Oxide Synthase (eNOS) gene expression and NO release to restore endothelial cell function.<sup>84</sup> Additionally, HG significantly inhibits the PI3K/Akt/eNOS signaling pathway, worsening apoptosis in Human Umbilical Vein Endothelial Cells. Moreover, the inhibitor of the PI3K/Akt/eNOS signaling pathway, LY294002, significantly suppresses the protective effect of H<sub>2</sub>S.<sup>85</sup> Liu et al discovered that H<sub>2</sub>S protects endothelial cells by enhancing autophagy via the Nrf2/ROS/AMPK pathway and reduces cell adhesion and apoptosis. H<sub>2</sub>S also promotes Nrf2 nuclear translocation, mitigating mitochondrial damage and inhibiting HG-induced ROS.<sup>86</sup> Li et al found that dopamine receptors boost the CSE/H<sub>2</sub>S pathway, increasing H<sub>2</sub>S levels. H<sub>2</sub>S inhibits HG-induced cell apoptosis in vascular endothelial cells by downregulating the NF-κB/ NF-kappa-B inhibitor alpha (IκBα) pathway and reduces excessive autophagy by decreasing AMPK activation due to ATP depletion.<sup>87</sup> Additionally, H<sub>2</sub>S improves excessive autophagy by reducing AMPK activation induced by ATP depletion, thus protecting endothelial cells induced by HG. Furthermore, Additionally, H<sub>2</sub>S significantly reduces necroptosis in HG-induced endothelial cells, a protective effect diminished by the Receptor-interacting protein kinase-3 (RIP3) inhibitor necrostatin-1 or RIP3-siRNA.<sup>88</sup> We have summarized the relevant findings in Table 2 to provide a clearer and more direct visualization of the target mechanisms of H<sub>2</sub>S.

## H<sub>2</sub>S Improves Angiogenesis

Endothelial cell angiogenesis, the process by which new blood vessels sprout from pre-existing vasculature, is essential for the repair of vascular injuries associated with diabetes.<sup>92,93</sup> Vascular damage, prevalent among diabetic patients, frequently results in diminished blood flow and tissue hypoxia.<sup>94</sup> Angiogenesis is critical for the repair and functional recovery of these injuries, with H<sub>2</sub>S identified as a significant promoter of endothelial cell angiogenesis.<sup>95</sup> Liu et al

**Table 2** H<sub>2</sub>S Improves HG Induced Endothelial Cell Death

Donor	Model	Pathway	Implication
NaHS	HG-induced HUVEC	PI3K/Akt/eNOS	Attenuate apoptosis <sup>85</sup>
API23	HG-induced BAEC	PI3K/CREB/eNOS	Restore endothelial function and attenuate apoptosis <sup>84</sup>
NaHS	Db/db mice	Nrf2/ROS/AMPK	Attenuate autophagy <sup>86</sup>
NaHS	HG+PA-induced RAEC		
NaHS	HG-induced HUVEC	NA	Attenuate necroptosis and apoptosis <sup>89</sup>
NaHS	HG-induced HUVEC	NA	Attenuate apoptosis <sup>90</sup>
NaHS	HG-induced HUVEC	NF-κB/IκBα	Attenuate apoptosis <sup>91</sup>
NaHS	HG+PA-induced RAEC	CSE/H <sub>2</sub> S	Attenuate apoptosis and mitophagy <sup>51</sup>
NaHS	HG-induced HUVEC	AMPK	Attenuate necroptosis <sup>88</sup>

**Abbreviations:** HUVEC, Human Umbilical Vein Endothelial Cells; BAEC, Bovine Aortic Endothelial Cell; RAEC, Rat aortic endothelial cell.

underscored the pivotal role of H<sub>2</sub>S in facilitating endothelial cell angiogenesis, particularly through the enhancement of angiogenesis and wound healing by restoring Angiopoietin 1/CSE expression.<sup>96</sup> Exogenous H<sub>2</sub>S can enhance endothelial cell angiogenesis in diabetic mice by modulating the miR-126-3p/DNA methyltransferase 1 pathway. In cell-based experiments, elevated H<sub>2</sub>S levels were primarily achieved through CSE overexpression, which led to increased miR-126-3p transcription and amelioration of diabetes-induced endothelial cell injury.<sup>97</sup> Moreover, microvascular relaxant 3-MP elevates circulating H<sub>2</sub>S levels, thereby stimulating endothelial cell angiogenesis by influencing 3-MST to boost H<sub>2</sub>S production.<sup>98</sup> Furthermore, lipoic acid acts as an activator of 3-MST, thereby amplifying the pro-angiogenic effects of 3-MP and promoting the restoration of endothelial cell function. In a parallel study, Lin's engineered particles, which are designed for sustained H<sub>2</sub>S release, have demonstrated that the H<sub>2</sub>S released by these particles enhances endothelial cell proliferation and migration, stimulates angiogenesis, and accelerates the healing of full-thickness wounds in diabetic mice by prolonging the activation of AMPK isoforms AMPK3 and AMPK14.<sup>99</sup>

## Interaction Between H<sub>2</sub>S and NO

NO is integral to both the functional regulation and pathological processes of endothelial cells. It is synthesized by various cell types via the oxidation of L-arginine, a reaction catalyzed by nitric oxide synthase (NOS). NOS is present in three distinct isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and eNOS.<sup>100</sup> NO is essential for the maintenance of vascular health and functionality. Within the cardiovascular system, nitric oxide is predominantly synthesized by eNOS.<sup>101</sup> eNOS catalyzes the conversion of L-arginine into NO and L-citrulline.<sup>102</sup> NO primarily facilitates vasodilation, exhibits anti-inflammatory and anti-adhesive properties, and possesses antioxidant capabilities.<sup>103,104</sup> Deficiency in NO can disrupt vascular homeostasis and modify endothelial permeability. Previous research has substantiated the role of NO in HG-induced endothelial cell damage, underscoring the necessity of targeted NO therapy for mitigating endothelial cell injuries. In recent years, researchers have explored the interaction between H<sub>2</sub>S and NO in endothelial cells subjected to HG. Treatment with NaHS has been demonstrated to mitigate the elevated activity of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase induced by diabetes, thereby restoring NO levels and reversing diabetes-induced vascular dysfunction, as well as decreasing superoxide production in the mouse aorta.<sup>105</sup> Under HG conditions, bovine aortic endothelial cells exhibit reduced NO levels, decreased eNOS expression, and inhibition of CREB. Treatment with API23 has been shown to rescue eNOS expression, increased NO levels, and restored the HG environment. Notably, the protective effects of H<sub>2</sub>S were significantly diminished by Wortmannin, a specific PI3K inhibitor, highlighting the crucial role of the PI3K pathway in mediating H<sub>2</sub>S-induced endothelial protection and the restoration of vasodilation function. This finding suggests that H<sub>2</sub>S enhances NO production and protects endothelial cells through the H<sub>2</sub>S/PI3K/CREB/eNOS signaling axis.<sup>84</sup> Conversely, Li proposes that H<sub>2</sub>S amplifies the protective effects of NO produced by iNOS, rather than eNOS, on endothelial cells. The application of iNOS siRNA and a selective iNOS inhibitor eliminates the protective effects of NaHS against hyperglycemia-induced




upregulation of NOX4 expression, excessive ROS generation, and aberrant matrix laminin expression, thereby aggravating endothelial damage in diabetic nephropathy.<sup>106</sup>

Hydroxylamine (HNO), the one-electron reduction product of NO, has emerged as a promising cardioprotective molecule. It improves myocardial injury by enhancing eNOS activity and reducing oxidative stress, thereby promoting NO production and maintaining vascular relaxation.<sup>107</sup> Additionally, HNO interacts with caveolin-3 to protect cardiomyocytes and reduce ischemia/reperfusion injury. Compared to traditional NO donors, HNO has a lower risk of tolerance, making it a promising candidate for cardiovascular protection.<sup>108</sup> Research has demonstrated that H<sub>2</sub>S can interact with NO to form HNO, which plays a crucial role in preserving cardiac function under pathological conditions. HNO has been shown to effectively prevent HG-induced myocardial cell injury in both in vivo and in vitro models. The underlying mechanism involves HNO restoring the interaction between caveolin-3 and eNOS, thereby enhancing NO production, reducing oxidative stress, alleviating mitochondrial dysfunction in myocardial cells, and ameliorating myocardial cell injuries.<sup>109</sup> In conclusion, we posit that H<sub>2</sub>S and NO exhibit complementary roles. H<sub>2</sub>S can activate NOS to produce NO, and it can also react with NO to generate HNO. These substances are all key targets in protecting endothelial cells or myocardial cells. To better illustrate this interaction, we have created a schematic diagram depicting the relationship between H<sub>2</sub>S and NO (Figure 4).

## Material Design Based on H<sub>2</sub>S

With the progression of technological advancements, an increasing number of research teams are focusing on the design of nanoparticles and materials that incorporate H<sub>2</sub>S for targeted delivery or enhanced therapeutic efficacy, grounded in a comprehensive understanding the role of H<sub>2</sub>S. These H<sub>2</sub>S-based biomaterials are particularly applicable in the treatment of diabetic wound healing. In hyperglycemic environments, where H<sub>2</sub>S synthesis is diminished, Lin et al have developed a novel lotion technology to mitigate this challenge. This innovative approach minimizes the degradation of water-unstable active compounds during the emulsification process, resulting in the formation of sodium hydrosulfide-loaded microparticles (NaHS@MPs). These particles act as in-situ storage, continuously releasing H<sub>2</sub>S under physiological conditions, which promotes cellular processes like cell proliferation, migration, and angiogenesis by extending ERK1/2 and p38 activation, thus speeding up wound healing in diabetic mice.<sup>99</sup> Additionally, Cao's team developed an antibiotic-free antibacterial protein hydrogel (H<sub>2</sub>S hydrogel). The hydrogel produces H<sub>2</sub>S gas for diabetes wound healing by combining bovine serum albumin gold nanoclusters (BSA AuNCs) with bis [tetra (hydroxymethyl) phosphonium] sulfate



**Figure 4** Interaction between H<sub>2</sub>S and NO.

**Abbreviations:** NADPH, Nicotinamide Adenine Dinucleotide Phosphate; iNOS, inducible NOS; eNOS, endothelial Nitric Oxide Synthase; PI3K, Phosphoinositide 3-kinase; CREB, cAMP response element-binding protein.

(THPS). A Mannich reaction crosslinks the amino group in BSA with the aldehyde group in THPS, creating a stable structure. After THPS hydrolysis, the resulting tris (hydroxymethyl) phosphorus reduces disulfide bonds in BSA to thiol groups, which then catalyze H<sub>2</sub>S gas generation by BSA AuNCs. THPS in the H<sub>2</sub>S hydrogel disrupts bacterial biofilm and inhibits oxidative stress, aiding cell proliferation, migration, angiogenesis, and wound healing, thus reducing diabetes-related wound injuries.<sup>110</sup> The He team created three quercetin-H<sub>2</sub>S donor conjugates that show potential in treating HG-induced insulin resistance, promoting endothelial cell proliferation, wound healing, and tubular formation in vitro.<sup>111</sup>

## H<sub>2</sub>S Improves Diabetic Nephropathy

In diabetes-induced endothelial damage, diabetic nephropathy is common, and H<sub>2</sub>S can treat it. Charlotte et al discovered that Anserine and Carnosine protect against diabetic nephropathy by acting on Heat Shock Protein (Hsp70) in endothelial and proximal tubular epithelial cells, boosting endogenous H<sub>2</sub>S expression. This reduces recombinant peptidase activity, decreases Anserine and Carnosine degradation, and enhances endothelial cell function in diabetic nephropathy.<sup>112</sup> Research indicates that GYY4137 can upregulate miR-194 in diabetic glomerular endothelial cells, reducing fibrosis and collagen synthesis. Inhibiting miR-194 worsens fibrosis, while its upregulation by GYY4137 decreases collagen and reactive oxygen species.<sup>113</sup> Kundu et al found that HG levels in kidney glomerular endothelial cells increase Matrix Metalloproteinase 9 (MMP9), decrease H<sub>2</sub>S production, induce NMDA-R1, and disrupt connexin-40 and connexin-43. Silencing MMP9 or inhibiting NMDA-R1 preserves connexin-40 and connexin-43. Thus, MMP9 is crucial in diabetes-related renal vascular remodeling, likely via the H<sub>2</sub>S/NMDA-R1 pathway.<sup>114</sup> Additionally, HG reduces the regulatory enzymes CBS and CSE, as well as autophagic markers Autophagy Related 5, Autophagy Related 7, Autophagy Related 3, and the LC3B/A ratio, while increasing, the markers of matrix accumulation (galectin-3 and osteopontin) in diabetic nephropathy.

NaHS treatment boosts liver kinase B1 (LKB1)/ STE20-related adaptor (STRAD)/ mouse protein 25 (MO25) complex formation and AMPK phosphorylation in HG cells. H<sub>2</sub>S counters HG-induced damage by promoting autophagy and regulating matrix metabolism via the LKB1/STRAD/MO25 pathway.<sup>115</sup> Additionally, HG increases NOX4 expression and activity in renal proximal tubular cells, but H<sub>2</sub>S induces iNOS to produce NO, which inhibits NOX4 expression, oxidative stress, and protecting renal epithelial cells from matrix accumulation.<sup>106</sup>

## H<sub>2</sub>S Improves Other Diabetes-Related Complications Associated with Endothelial Cells

Several studies indicate that H<sub>2</sub>S can alleviate endothelial cell complications, enhance wound healing in diabetic rats, and treat diabetes-induced retinopathy. These benefits are linked to granulation tissue formation, anti-inflammatory and antioxidant effects, increased vascular endothelial growth factor<sup>116</sup>, and reduced oxidative stress, mitochondrial damage, and MMP9 production. GYY4137, a specific H<sub>2</sub>S donor, is particularly effective in preventing retinopathy. H<sub>2</sub>S also serves as a potential biomarker for tracking the progression of diabetic retinopathy.<sup>117</sup> H<sub>2</sub>S donors protect retinal endothelial cells from apoptosis under HG conditions.<sup>91</sup> Compounds like GYY4137 and AP39 preserve the retinal glycocalyx and endothelial permeability, slowing diabetic retinopathy progression.<sup>118</sup> Moreover, H<sub>2</sub>S helps manage diabetic neuropathy by inhibiting apoptosis and inflammation pathways in the spinal cord.<sup>119</sup>

## Dose-Response Relationships and Potential Side Effects of H<sub>2</sub>S and Its Donors

The use of H<sub>2</sub>S-based approaches in therapeutic applications offers several strengths, but also comes with limitations. One of the main advantages of H<sub>2</sub>S therapy is its dose-dependent protective effects. At low to moderate doses, H<sub>2</sub>S has been shown to improve cardiovascular function, reduce inflammation, and protect against cellular damage. For instance, inhalation of 40–80 ppm H<sub>2</sub>S has demonstrated anti-inflammatory effects in animal models, making it a promising candidate for treating conditions like heart failure and acute lung injury.<sup>120–122</sup> Moreover, H<sub>2</sub>S can help restore mitochondrial function and regulate ion channels, which are essential for cellular homeostasis.

However, there are notable limitations associated with H<sub>2</sub>S-based therapies. High doses of H<sub>2</sub>S, such as 100–300 ppm, have been linked to significant side effects, including hypoxemia, pulmonary vasoconstriction, and systemic vasodilation, which can be harmful to the cardiovascular and respiratory systems.<sup>122</sup> Additionally, the rapid dissociation of inorganic H<sub>2</sub>S donors, like NaHS and Na<sub>2</sub>S, may lead to lower-than-expected concentrations of H<sub>2</sub>S, reducing the therapeutic efficacy.<sup>123</sup> The release of potentially toxic by-products, such as formaldehyde and carbon monoxide, from some synthetic H<sub>2</sub>S donors (GYY4137), adds another layer of complexity and risk to their clinical use.<sup>124</sup> Therefore, while H<sub>2</sub>S-based approaches hold significant therapeutic potential, careful consideration of dose-response relationships and the management of side effects is crucial for their safe and effective clinical application.

## Comparative Evaluation of H<sub>2</sub>S Donors in Endothelial Dysfunction and Their Translational Potential

Different H<sub>2</sub>S donors exhibit distinct therapeutic effects on high glucose-induced endothelial dysfunction, each with unique release mechanisms and pharmacological properties. GYY4137, a slow-releasing H<sub>2</sub>S donor, provides sustained H<sub>2</sub>S delivery, effectively reducing oxidative stress, inflammation, and apoptosis, making it suitable for long-term management of diabetic vascular complications. AP39, a mitochondria-targeted donor, selectively delivers H<sub>2</sub>S to mitochondria, enhancing mitochondrial function and reducing oxidative damage, offering significant potential for addressing mitochondrial dysfunction in diabetic cardiovascular diseases. In contrast, NaHS, an inorganic donor that rapidly releases H<sub>2</sub>S, can acutely improve endothelial function by enhancing vasodilation, but its effects are short-lived due to rapid oxidation and degradation, making it more suitable for acute interventions rather than sustained treatment. However, the pharmacokinetics and potential off-target effects of these donors require further investigation. While GYY4137 ensures prolonged H<sub>2</sub>S release, its systemic bioavailability and long-term metabolic fate remain unclear. AP39's mitochondria-targeting ability raises questions about its selectivity and possible interactions with other mitochondrial pathways. NaHS, due to its rapid degradation, may lead to transient spikes in H<sub>2</sub>S levels, potentially affecting unintended signaling pathways. Further research is necessary to optimize their clinical application and fully understand their therapeutic potential in treating diabetic vascular complications.

Compared to standard treatments, such as antioxidants (eg, NAC, vitamin C), NO donors (eg, nitrates), and anti-inflammatory drugs (eg, aspirin, statins), H<sub>2</sub>S donors offer a broader protective effect. While traditional antioxidants primarily scavenge reactive oxygen species (ROS), they have limited efficacy in targeting mitochondrial oxidative stress, whereas AP39 is particularly effective in this regard. NO donors improve vasodilation by increasing NO levels but may lead to tolerance with prolonged use, whereas H<sub>2</sub>S enhances eNOS activity and reduces NO degradation without inducing tolerance. Anti-inflammatory drugs mainly inhibit pro-inflammatory pathways like NF-κB but may have systemic side effects, whereas H<sub>2</sub>S donors not only suppress inflammation but also regulate oxidative stress, apoptosis, and autophagy, offering a more comprehensive protective effect.

Overall, AP39 holds the greatest potential for clinical translation due to its ability to specifically target mitochondria and mitigate oxidative damage, while GYY4137's sustained H<sub>2</sub>S release makes it more suitable for long-term vascular protection. NaHS, though effective in acute settings, may require combination with longer-acting H<sub>2</sub>S donors for sustained benefits. Given their multifaceted protective mechanisms, H<sub>2</sub>S donors, particularly AP39 and GYY4137, may offer superior therapeutic advantages over conventional treatments, highlighting their potential for clinical application in diabetes-related vascular dysfunction.

## Limitation

In the treatment of diabetes-induced cardiovascular complications, the use of H<sub>2</sub>S still faces several challenges. First, despite its promising potential, identifying optimal H<sub>2</sub>S donors remains a major obstacle. Current mainstream H<sub>2</sub>S donors include NaHS, GYY4137, AP39, and AP123, as well as others such as JK-1, JK-2,<sup>125</sup> NSHD-1, NSHD-2, NSHD-6,<sup>126</sup> or garlic extracts.<sup>127</sup> However, no H<sub>2</sub>S donor has entered clinical research to demonstrate its efficacy in improving diabetes-induced myocardial or endothelial cell damage, necessitating further evaluation of the clinical prospects of these compounds. Second, although materials have been developed to deliver H<sub>2</sub>S stably, ensuring its sustained and effective

release for treating other diabetic complications such as diabetic cardiomyopathy and diabetic nephropathy remains challenging. Therefore, it is crucial to identify or design safe and effective H<sub>2</sub>S donor materials to address diabetes-related complications. Furthermore, many existing H<sub>2</sub>S donors lack tissue or cell specificity, thus failing to precisely target the desired tissues or cells and potentially causing nonspecific effects. After that, the safety of H<sub>2</sub>S donors must be thoroughly assessed in preclinical trials, including evaluating potential side effects and interactions with other medications commonly used by diabetic patients.

## Conclusion

Diabetes-induced myocardial and endothelial cell damage serves as the pathological basis for diabetic cardiomyopathy, diabetic microvascular disease, and diabetic nephropathy. Developing effective therapeutic strategies to mitigate these injuries is crucial for improving patient outcomes. As a bioactive gasotransmitter similar to NO and CO, hydrogen sulfide (H<sub>2</sub>S) has demonstrated significant protective effects in cardiovascular diseases. Its mechanisms of action primarily involve S-sulphydration of proteins, which helps mitigate cell death, reduce mitochondrial damage, regulate ion channel function, and promote vascular regeneration.

Despite its promising therapeutic potential, the clinical translation of H<sub>2</sub>S-based therapies faces challenges, particularly in optimizing dose-response relationships and minimizing potential side effects. While low-to-moderate doses exhibit protective effects, high concentrations can induce toxicity, such as vascular dysfunction and metabolic disturbances. Additionally, different H<sub>2</sub>S delivery methods—including direct inhalation, inorganic sulfides, natural donors, and synthetic compounds—each have distinct advantages and limitations in terms of stability, controlled release, and clinical applicability.

Future research should focus on refining H<sub>2</sub>S donor compounds to achieve precise, targeted, and sustained release while minimizing off-target effects. The development of novel prodrugs, enzyme-responsive H<sub>2</sub>S donors, and mitochondria-targeted compounds holds promise for enhancing therapeutic efficacy. Furthermore, large-scale clinical trials are necessary to validate the safety, pharmacokinetics, and long-term benefits of H<sub>2</sub>S-based treatments. By addressing these challenges, H<sub>2</sub>S may emerge as a viable therapeutic strategy for mitigating diabetes-associated cardiovascular and microvascular complications, ultimately improving disease.

## Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

## Funding

This research was supported by Zhejiang Province Medical and Health Project (2023KY1242 and 2022KY1303).

## Disclosure

The authors declare no competing interests in this work.

## References

1. Beauchamp RO Jr, Bus JS, Popp JA, Boreiko CJ, Andjelkovich DA. A critical review of the literature on hydrogen sulfide toxicity. *Crit Rev Toxicol.* 1984;13(1):25–97. doi:10.3109/10408448409029321
2. Fiedler N, Kipen H, Ohman-Strickland P, et al. Sensory and cognitive effects of acute exposure to hydrogen sulfide. *Environ Health Perspect.* 2008;116(1):78–85. doi:10.1289/ehp.10531
3. Kolluru GK, Shackelford RE, Shen X, Dominic P, Kevil CG. Sulfide regulation of cardiovascular function in health and disease. *Nat Rev Cardiol.* 2023;20(2):109–125.
4. Hu Q, Lukesh JC. H(2)S donors with cytoprotective effects in models of mi/r injury and chemotherapy-induced cardiotoxicity. *Antioxidants.* 2023;12(3):650. doi:10.3390/antiox12030650
5. Song Y, Xu Z, Zhong Q, Zhang R, Sun X, Chen G. Sulfur signaling pathway in cardiovascular disease. *Front Pharmacol.* 2023;14:1303465. doi:10.3389/fphar.2023.1303465

6. Cuevasanta E, Lange M, Bonanata J, et al. Reaction of hydrogen sulfide with disulfide and sulfenic acid to form the strongly nucleophilic persulfide. *J Biol Chem*. 2015;290(45):26866–26880. doi:10.1074/jbc.M115.672816
7. Fukuto JM, Carrington SJ, Tantillo DJ, et al. Small molecule signaling agents: the integrated chemistry and biochemistry of nitrogen oxides, oxides of carbon, dioxygen, hydrogen sulfide, and their derived species. *Chem Res Toxicol*. 2012;25(4):769–793. doi:10.1021/tx2005234
8. Cao X, Ding L, Xie ZZ, et al. A review of hydrogen sulfide synthesis, metabolism, and measurement: is modulation of hydrogen sulfide a novel therapeutic for cancer? *Antioxid Redox Signal*. 2019;31(1):1–38. doi:10.1089/ars.2017.7058
9. Kimura H. Hydrogen sulfide: its production, release and functions. *Amino Acids*. 2011;41(1):113–121. doi:10.1007/s00726-010-0510-x
10. Li M, Mao J, Zhu Y. New therapeutic approaches using hydrogen sulfide donors in inflammation and immune response. *Antioxid Redox Signal*. 2021;35(5):341–356. doi:10.1089/ars.2020.8249
11. Whiteman M, Winyard PG. Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising. *Expert Rev Clin Pharmacol*. 2011;4(1):13–32. doi:10.1586/ecp.10.134
12. Papapetropoulos A, Pyriochou A, Altaany Z, et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. *Proc Natl Acad Sci U S A*. 2009;106(51):21972–21977.
13. Li X, Xu Z, Huang T, et al. Investigating the research trajectory and future trends of immune disorders in diabetes cardiovascular complications: a bibliometric analysis over the past decade based on big data. *Ageing Res Rev*. 2024;101:102473. doi:10.1016/j.arr.2024.102473
14. ElSayed NA, Aleppo G, Bannuru RR. 2. diagnosis and classification of diabetes: standards of care in Diabetes—2024. *Diabetes Care*. 2024;47(Suppl 1):S20–s42. doi:10.2337/dc24-S002
15. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. *Circulation*. 2000;101(19):2271–2276. doi:10.1161/01.CIR.101.19.2271
16. Bugger H, Abel ED, Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. *Diabetologia*. 2014;57(4):660–671. doi:10.1007/s00125-014-3171-6
17. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol*. 2018;14(2):88–98. doi:10.1038/nrendo.2017.151
18. Demir S, Nawroth PP, Herzig S, B EÜ. Emerging targets in type 2 diabetes and diabetic complications. *Adv Sci*. 2021;8(18):e2100275. doi:10.1002/adv.202100275
19. Ali MK, Pearson-Stuttard J, Selvin E, Gregg EW. Interpreting global trends in type 2 diabetes complications and mortality. *Diabetologia*. 2022;65(1):3–13. doi:10.1007/s00125-021-05585-2
20. Miles EW, Kraus JP. Cystathionine beta-synthase: structure, function, regulation, and location of homocystinuria-causing mutations. *J Biol Chem*. 2004;279(29):29871–29874. doi:10.1074/jbc.R400005200
21. Pan LL, Liu XH, Gong QH, Yang HB, Zhu YZ. Role of cystathionine  $\gamma$ -lyase/hydrogen sulfide pathway in cardiovascular disease: a novel therapeutic strategy? *Antioxid Redox Signal*. 2012;17(1):106–118. doi:10.1089/ars.2011.4349
22. Shibuya N, Tanaka M, Yoshida M, et al. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid Redox Signal*. 2009;11(4):703–714. doi:10.1089/ars.2008.2253
23. Kolluru GK, Shen X, Bir SC, Kevil CG. Hydrogen sulfide chemical biology: pathophysiological roles and detection. *Nitric Oxide*. 2013;35:5–20. doi:10.1016/j.niox.2013.07.002
24. Kolluru GK, Shen X, Kevil CG. Reactive sulfur species: a new redox player in cardiovascular pathophysiology. *Arterioscler Thromb Vasc Biol*. 2020;40(4):874–884. doi:10.1161/ATVBAHA.120.314084
25. Yang J, Minkler P, Grove D, et al. Non-enzymatic hydrogen sulfide production from cysteine in blood is catalyzed by iron and vitamin B(6). *Commun Biol*. 2019;2:194. doi:10.1038/s42003-019-0431-5
26. Shibuya N, Koike S, Tanaka M, et al. A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells. *Nat Commun*. 2013;4:1366. doi:10.1038/ncomms2371
27. Kaneko Y, Kimura Y, Kimura H, Niki I. L-cysteine inhibits insulin release from the pancreatic beta-cell: possible involvement of metabolic production of hydrogen sulfide, a novel gasotransmitter. *Diabetes*. 2006;55(5):1391–1397. doi:10.2337/db05-1082
28. Nagahara N, Ito T, Kitamura H, Nishino T. Tissue and subcellular distribution of mercaptopyruvate sulfurtransferase in the rat: confocal laser fluorescence and immunoelectron microscopic studies combined with biochemical analysis. *Histochem Cell Biol*. 1998;110(3):243–250. doi:10.1007/s004180050286
29. Sun Y, Lu F, Yu X, et al. Exogenous H(2)S promoted USP8 sulphydration to regulate mitophagy in the hearts of db/db mice. *Aging Dis*. 2020;11(2):269–285. doi:10.14336/AD.2019.0524
30. Peng S, Wang M, Zhang S, et al. Hydrogen sulfide regulates SERCA2a SUMOylation by S-Sulphydration of SENP1 to ameliorate cardiac systole-diastole function in diabetic cardiomyopathy. *Biomed Pharmacother*. 2023;160:114200.
31. Insko MA, Deckwerth TL, Hill P, Toombs CF, Szabo C. Detection of exhaled hydrogen sulphide gas in rats exposed to intravenous sodium sulphide. *Br J Pharmacol*. 2009;157(6):944–951. doi:10.1111/j.1476-5381.2009.00248.x
32. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. *Physiol Rev*. 2012;92(2):791–896. doi:10.1152/physrev.00017.2011
33. Stipanuk MH, Ueki I. Dealing with methionine/homocysteine sulfur: cysteine metabolism to taurine and inorganic sulfur. *J Inherit Metab Dis*. 2011;34(1):17–32. doi:10.1007/s10545-009-9006-9
34. Jackson MR, Melideo SL, Jorns MS. Role of human sulfide: quinone oxidoreductase in H<sub>2</sub>S metabolism. *Methods Enzymol*. 2015;554:255–270.
35. Jackson MR, Melideo SL, Jorns MS. Human sulfide: quinone oxidoreductase catalyzes the first step in hydrogen sulfide metabolism and produces a sulfane sulfur metabolite. *Biochemistry*. 2012;51(34):6804–6815. doi:10.1021/bi300778t
36. Weisiger RA, Pinkus LM, Jakoby WB. Thiol S-methyltransferase: suggested role in detoxication of intestinal hydrogen sulfide. *Biochem Pharmacol*. 1980;29(20):2885–2887. doi:10.1016/0006-2952(80)90029-5
37. Kolluru GK, Shen X, Kevil CG. A tale of two gases: NO and H<sub>2</sub>S, foes or friends for life? *Redox Biol*. 2013;1(1):313–318. doi:10.1016/j.redox.2013.05.001
38. Sun X, Zhao D, Lu F, et al. Hydrogen sulfide regulates muscle RING finger-1 protein S-sulphydration at Cys(44) to prevent cardiac structural damage in diabetic cardiomyopathy. *Br J Pharmacol*. 2020;177(4):836–856. doi:10.1111/bph.14601



39. Yu M, Du H, Wang B, et al. Exogenous H(2)S induces Hrd1 S-sulphydration and prevents CD36 translocation via VAMP3 ubiquitylation in diabetic hearts. *Aging Dis.* **2020**;11(2):286–300. doi:10.14336/AD.2019.0530
40. Sun Y, Zhang L, Lu B, et al. Hydrogen sulphide reduced the accumulation of lipid droplets in cardiac tissues of db/db mice via Hrd1 S-sulphydration. *J Cell Mol Med.* **2021**;25(19):9154–9167. doi:10.1111/jcmm.16781
41. Zhang S, Wang M, Li H, et al. Exogenous H(2) S promotes ubiquitin-mediated degradation of SREBP1 to alleviate diabetic cardiomyopathy via SYVN1 S-sulphydration. *J Cachexia Sarcopenia Muscle.* **2023**;14(6):2719–2732. doi:10.1002/jcsm.13347
42. Peng S, Zhao D, Li Q, et al. Hydrogen sulfide regulates SERCA2a ubiquitylation via muscle RING finger-1 S-sulphydration to affect cardiac contractility in db/db mice. *Cells.* **2022**;11(21):3465. doi:10.3390/cells11213465
43. Wang M, Tang J, Zhang S, et al. Exogenous H(2)S initiating Nrf2/GPx4/GSH pathway through promoting Syvn1-Keap1 interaction in diabetic hearts. *Cell Death Discov.* **2023**;9(1):394. doi:10.1038/s41420-023-01690-w
44. Xie L, Gu Y, Wen M, et al. Hydrogen sulfide induces Keap1 S-sulphydration and suppresses diabetes-accelerated atherosclerosis via Nrf2 activation. *Diabetes.* **2016**;65(10):3171–3184. doi:10.2337/db16-0020
45. Monzel AS, Enriquez JA, Picard M. Multifaceted mitochondrial science beyond function and dysfunction. *Nat Metab.* **2023**;5(4):546–562. doi:10.1038/s42255-023-00783-1
46. Li A, Gao M, Liu B, et al. Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease. *Cell Death Dis.* **2022**;13(5):444.
47. Chang X, Li Y, Cai C, et al. Mitochondrial quality control mechanisms as molecular targets in diabetic heart. *Metabolism.* **2022**;137:155313.
48. Zhong X, Wang L, Wang Y, et al. Exogenous hydrogen sulfide attenuates diabetic myocardial injury through cardiac mitochondrial protection. *mol Cell Biochem.* **2012**;371(1–2):187–198. doi:10.1007/s11010-012-1435-3
49. Yang F, Yu X, Li T, et al. Exogenous H(2)S regulates endoplasmic reticulum-mitochondria cross-talk to inhibit apoptotic pathways in STZ-induced type I diabetes. *Am J Physiol Endocrinol Metab.* **2017**;312(3):E190–e203. doi:10.1152/ajpendo.00196.2016
50. Sun Y, Teng Z, Sun X, et al. Exogenous H(2)S reduces the acetylation levels of mitochondrial respiratory enzymes via regulating the NAD (+)-SIRT3 pathway in cardiac tissues of db/db mice. *Am J Physiol Endocrinol Metab.* **2019**;317(2):E284–e97. doi:10.1152/ajpendo.00326.2018
51. Liu N, Wu J, Zhang L, et al. Hydrogen Sulphide modulating mitochondrial morphology to promote mitophagy in endothelial cells under high-glucose and high-palmitate. *J Cell Mol Med.* **2017**;21(12):3190–3203. doi:10.1111/jcmm.13223
52. Gerő D, Torregrossa R, Perry A, et al. The novel mitochondria-targeted hydrogen sulfide (H(2)S) donors AP123 and AP39 protect against hyperglycemic injury in microvascular endothelial cells in vitro. *Pharmacol Res.* **2016**;113(Pt A):186–198. doi:10.1016/j.phrs.2016.08.019
53. Suzuki K, Olah G, Modis K, et al. Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. *Proc Natl Acad Sci U S A.* **2011**;108(33):13829–13834. doi:10.1073/pnas.1105121108
54. Testai L, Montanaro R, Flori L, et al. Persulfidation of mitoKv7.4 channels contributes to the cardioprotective effects of the H(2)S-donor Erucin against ischemia/reperfusion injury. *Biochem Pharmacol.* **2023**;215:115728. doi:10.1016/j.bcp.2023.115728
55. Wu D, Tan B, Sun Y, Hu Q. Cystathionine  $\gamma$  lyase S-sulphydrates Drp1 to ameliorate heart dysfunction. *Redox Biol.* **2022**;58:102519. doi:10.1016/j.redox.2022.102519
56. Liang W, Chen J, Mo L, et al. ATP-sensitive K<sup>+</sup> channels contribute to the protective effects of exogenous hydrogen sulfide against high glucose-induced injury in H9c2 cardiac cells. *Int J Mol Med.* **2016**;37(3):763–772. doi:10.3892/ijmm.2016.2467
57. Papu John AS, Kundu S, Pushpakumar S, Amin M, Tyagi SC, Sen U. Hydrogen sulfide inhibits Ca(2+)-induced mitochondrial permeability transition pore opening in type-1 diabetes. *Am J Physiol Endocrinol Metab.* **2019**;317(2):E269–e83. doi:10.1152/ajpendo.00251.2018
58. Pistritto G, Triscioglio D, Ceci C, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. *Aging.* **2016**;8(4):603–619. doi:10.18632/aging.100934
59. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol.* **2007**;35(4):495–516. doi:10.1080/01926230701320337
60. Fleisher TA. Apoptosis. *Ann Allergy Asthma Immunol.* **1997**;78(3):245–9;quiz9–50. doi:10.1016/S1081-1206(10)63176-6
61. Barr LA, Shimizu Y, Lambert JP, Nicholson CK, Calvert JW. Hydrogen sulfide attenuates high fat diet-induced cardiac dysfunction via the suppression of endoplasmic reticulum stress. *Nitric Oxide.* **2015**;46:145–156. doi:10.1016/j.niox.2014.12.013
62. Li F, Luo J, Wu Z, et al. Hydrogen sulfide exhibits cardioprotective effects by decreasing endoplasmic reticulum stress in a diabetic cardiomyopathy rat model. *Mol Med Rep.* **2016**;14(1):865–873. doi:10.3892/mmr.2016.5289
63. Jeong SY, Seol DW. The role of mitochondria in apoptosis. *BMB Rep.* **2008**;41(1):11–22. doi:10.5483/BMBRep.2008.41.1.011
64. Green DR. The Mitochondrial Pathway of Apoptosis: part I: MOMP and Beyond. *Cold Spring Harb Perspect Biol.* **2022**;14(5):a041038.
65. Zhang J, Guo J, Yang N, Huang Y, Hu T, Rao C. Endoplasmic reticulum stress-mediated cell death in liver injury. *Cell Death Dis.* **2022**;13(12):1051. doi:10.1038/s41419-022-05444-x
66. Abate M, Festa A, Falco M, et al. Mitochondria as playmakers of apoptosis, autophagy and senescence. *Semin Cell Dev Biol.* **2020**;98:139–153.
67. Zhao Y, Hu X, Liu Y, et al. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. *mol Cancer.* **2017**;16(1):79. doi:10.1186/s12943-017-0648-1
68. Trefts E, Shaw RJ. AMPK: restoring metabolic homeostasis over space and time. *Mol Cell.* **2021**;81(18):3677–3690. doi:10.1016/j.molcel.2021.08.015
69. Zhou X, An G, Lu X. Hydrogen sulfide attenuates the development of diabetic cardiomyopathy. *Clin Sci.* **2015**;128(5):325–335. doi:10.1042/CS20140460
70. Guo R, Wu Z, Jiang J, et al. New mechanism of lipotoxicity in diabetic cardiomyopathy: deficiency of Endogenous H(2)S Production and ER stress. *Mech Ageing Dev.* **2017**;162:46–52. doi:10.1016/j.mad.2016.11.005
71. Yang H, Mao Y, Tan B, Luo S, Zhu Y. The protective effects of endogenous hydrogen sulfide modulator, S-propargyl-cysteine, on high glucose-induced apoptosis in cardiomyocytes: a novel mechanism mediated by the activation of Nrf2. *Eur J Pharmacol.* **2015**;761:135–143.
72. Xu W, Wu W, Chen J, et al. Exogenous hydrogen sulfide protects H9c2 cardiac cells against high glucose-induced injury by inhibiting the activities of the p38 MAPK and ERK1/2 pathways. *Int J Mol Med.* **2013**;32(4):917–925. doi:10.3892/ijmm.2013.1462
73. Huang Z, Dong X, Zhuang X, Hu X, Wang L, Liao X. Exogenous hydrogen sulfide protects against high glucose-induced inflammation and cytotoxicity in H9c2 cardiac cells. *Mol Med Rep.* **2016**;14(5):4911–4917. doi:10.3892/mmr.2016.5846
74. Tsai CY, Wen SY, Shibu MA, et al. Diallyl trisulfide protects against high glucose-induced cardiac apoptosis by stimulating the production of cystathionine gamma-lyase-derived hydrogen sulfide. *Int J Cardiol.* **2015**;195:300–310. doi:10.1016/j.ijcard.2015.05.111

75. Huang Z, Zhuang X, Xie C, et al. Exogenous hydrogen sulfide attenuates high glucose-induced cardiotoxicity by inhibiting NLRP3 inflammasome activation by suppressing TLR4/NF- $\kappa$ B pathway in H9c2 cells. *Cell Physiol Biochem*. 2016;40(6):1578–1590. doi:10.1159/000453208
76. Zhang M, Ye M. Hydrogen sulfide attenuates high glucose-induced myocardial injury in rat cardiomyocytes by suppressing wnt/beta-catenin pathway. *Curr Med Sci*. 2019;39(6):938–946. doi:10.1007/s11596-019-2120-5
77. Kar S, Shahshahan HR, Hackfort BT, et al. Exercise training promotes cardiac hydrogen sulfide biosynthesis and mitigates pyroptosis to prevent high-fat diet-induced diabetic cardiomyopathy. *Antioxidants*. 2019;8(12). doi:10.3390/antiox8120638
78. Gong W, Zhang S, Chen Y, et al. Protective role of hydrogen sulfide against diabetic cardiomyopathy via alleviating necroptosis. *Free Radic Biol Med*. 2022;181:29–42. doi:10.1016/j.freeradbiomed.2022.01.028
79. Zhang S, Shen J, Zhu Y, et al. Hydrogen sulfide promoted retinoic acid-related orphan receptor  $\alpha$  transcription to alleviate diabetic cardiomyopathy. *Biochem Pharmacol*. 2023;215:115748. doi:10.1016/j.bcp.2023.115748
80. Li Y, Liu M, Song X, et al. Exogenous hydrogen sulfide ameliorates diabetic myocardial fibrosis by inhibiting cell aging through SIRT6/AMPK autophagy. *Front Pharmacol*. 2020;11:1150. doi:10.3389/fphar.2020.01150
81. Wu J, Tian Z, Sun Y, et al. Exogenous H(2)S facilitating ubiquitin aggregates clearance via autophagy attenuates type 2 diabetes-induced cardiomyopathy. *Cell Death Dis*. 2017;8(8):e2992. doi:10.1038/cddis.2017.380
82. Liu M, Zeng C, Zhang Y, Xin Y, Deng S, Hu X. Protective role of hydrogen sulfide against diabetic cardiomyopathy by inhibiting pyroptosis and myocardial fibrosis. *Biomed Pharmacother*. 2024;175:116613. doi:10.1016/j.biopha.2024.116613
83. Zheng Q, Pan L, Ji Y. H (2)S protects against diabetes-accelerated atherosclerosis by preventing the activation of NLRP3 inflammasome. *J Biomed Res*. 2019;34(2):94–102. doi:10.7555/JBR.33.20190071
84. Montanaro R, Vellecco V, Torregrossa R, et al. Hydrogen sulfide donor AP123 restores endothelial nitric oxide-dependent vascular function in hyperglycemia via a CREB-dependent pathway. *Redox Biol*. 2023;62:102657. doi:10.1016/j.redox.2023.102657
85. Lin F, Yang Y, Wei S, et al. Hydrogen sulfide protects against high glucose-induced human umbilical vein endothelial cell injury through activating PI3K/Akt/eNOS pathway. *Drug Des Devel Ther*. 2020;14:621–633. doi:10.2147/DDDT.S242521
86. Liu J, Wu J, Sun A, et al. Hydrogen sulfide decreases high glucose/palmitate-induced autophagy in endothelial cells by the Nrf2-ROS-AMPK signaling pathway. *Cell Biosci*. 2016;6:33. doi:10.1186/s13578-016-0099-1
87. Li H, Wu R, Xi Y, et al. Dopamine 1 receptors inhibit apoptosis via activating CSE/H(2) S pathway in high glucose-induced vascular endothelial cells. *Cell Biol Int*. 2022;46(7):1098–1108. doi:10.1002/cbin.11794
88. Lin J, Li X, Lin Y, Huang Z, Wu W. Exogenous sodium hydrosulfide protects against high glucose-induced injury and inflammation in human umbilical vein endothelial cells by inhibiting necroptosis via the p38 MAPK signaling pathway. *Mol Med Rep*. 2021;23(1):1.
89. Lin J, Chen M, Liu D, et al. Exogenous hydrogen sulfide protects human umbilical vein endothelial cells against high glucose-induced injury by inhibiting the necroptosis pathway. *Int J Mol Med*. 2018;41(3):1477–1486. doi:10.3892/ijmm.2017.3330
90. Guan Q, Zhang Y, Yu C, Liu Y, Gao L, Zhao J. Hydrogen sulfide protects against high-glucose-induced apoptosis in endothelial cells. *J Cardiovasc Pharmacol*. 2012;59(2):188–193. doi:10.1097/FJC.0b013e31823b4915
91. Han Y, Zhang X, Zhou Z, et al. Hydrogen sulfide serves as a biomarker in the anterior segment of patients with diabetic retinopathy. *Int Ophthalmol*. 2020;40(4):891–899. doi:10.1007/s10792-019-01252-z
92. Rohlenova K, Veys K, Miranda-Santos I, De Bock K, Carmeliet P. Endothelial cell metabolism in health and disease. *Trends Cell Biol*. 2018;28(3):224–236. doi:10.1016/j.tcb.2017.10.010
93. Missiaen R, Morales-Rodriguez F, Eelen G, Carmeliet P. Targeting endothelial metabolism for anti-angiogenesis therapy: a pharmacological perspective. *Vascul Pharmacol*. 2017;90:8–18. doi:10.1016/j.vph.2017.01.001
94. Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. *J Diabetes*. 2017;9(5):434–449. doi:10.1111/1753-0407.12521
95. Luo Z, Yao J, Wang Z, Xu J. Mitochondria in endothelial cells angiogenesis and function: current understanding and future perspectives. *J Transl Med*. 2023;21(1):441. doi:10.1186/s12967-023-04286-1
96. Liu F, Chen DD, Sun X, et al. Hydrogen sulfide improves wound healing via restoration of endothelial progenitor cell functions and activation of angiotensinogen-converting enzyme in type 2 diabetes. *Diabetes*. 2014;63(5):1763–1778. doi:10.2337/db13-0483
97. Xue W, Zhang Q, Chen Y, Zhu Y. Hydrogen sulfide improves angiogenesis by regulating the transcription of pri-miR-126 in diabetic endothelial cells. *Cells*. 2022;11(17):2651. doi:10.3390/cells11172651
98. Coletta C, Módos K, Szczesny B, et al. Regulation of vascular tone, angiogenesis and cellular bioenergetics by the 3-mercaptopyruvate sulfurtransferase/H<sub>2</sub>S pathway: functional impairment by hyperglycemia and restoration by DL- $\alpha$ -lipoic acid. *Mol Med*. 2015;21(1):1–14. doi:10.2119/molmed.2015.00035
99. Lin WC, Huang CC, Lin SJ, et al. In situ depot comprising phase-change materials that can sustainably release a gasotransmitter H(2)S to treat diabetic wounds. *Biomaterials*. 2017;145:1–8. doi:10.1016/j.biomaterials.2017.08.023
100. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. *Physiol Rev*. 2004;84(3):731–765. doi:10.1152/physrev.00034.2003
101. Hong FF, Liang XY, Liu W, et al. Roles of eNOS in atherosclerosis treatment. *Inflamm Res*. 2019;68(6):429–441. doi:10.1007/s00011-019-01229-9
102. Robbins RA, Grisham MB. Nitric oxide. *Int J Biochem Cell Biol*. 1997;29(6):857–860. doi:10.1016/S1357-2725(96)00167-7
103. Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: redox pathways in molecular medicine. *Proc Natl Acad Sci U S A*. 2018;115(23):5839–5848. doi:10.1073/pnas.1804932115
104. Tegeder I. Nitric oxide mediated redox regulation of protein homeostasis. *Cell Signal*. 2019;53:348–356. doi:10.1016/j.cellsig.2018.10.019
105. Ng HH, Yildiz GS, Ku JM, Miller AA, Woodman OL, Hart JL. Chronic NaHS treatment decreases oxidative stress and improves endothelial function in diabetic mice. *Diab Vasc Dis Res*. 2017;14(3):246–253. doi:10.1177/1479164117692766
106. Lee HJ, Lee DY, Mariappan MM, et al. Hydrogen sulfide inhibits high glucose-induced NADPH oxidase 4 expression and matrix increase by recruiting inducible nitric oxide synthase in kidney proximal tubular epithelial cells. *J Biol Chem*. 2017;292(14):5665–5675. doi:10.1074/jbc.M116.766758
107. Fukuto JM, Carrington SJ. HNO signaling mechanisms. *Antioxid Redox Signal*. 2011;14(9):1649–1657. doi:10.1089/ars.2010.3855

108. Bullen ML, Miller AA, Andrews KL, et al. Nitroxyl (HNO) as a vasoprotective signaling molecule. *Antioxid Redox Signal*. 2011;14(9):1675–1686. doi:10.1089/ars.2010.3327
109. Sun HJ, Xiong SP, Wu ZY, et al. Induction of caveolin-3/eNOS complex by nitroxyl (HNO) ameliorates diabetic cardiomyopathy. *Redox Biol*. 2020;32:101493. doi:10.1016/j.redox.2020.101493
110. Cao Y, Jiang Y, Bai R, et al. A multifunctional protein-based hydrogel with Au nanozyme-mediated self generation of H(2)S for diabetic wound healing. *Int J Biol Macromol*. 2024;271(Pt 1):132560. doi:10.1016/j.ijbiomac.2024.132560
111. Mitidieri E, Tramontano T, Gurgone D, et al. Mercaptopyruvate acts as endogenous vasodilator independently of 3-mercaptopyruvate sulfurtransferase activity. *Nitric Oxide*. 2018;75:53–59. doi:10.1016/j.niox.2018.02.003
112. Wetzel C, Pfeffer T, Bulkescher R, et al. Anserine and carnosine induce HSP70-dependent H(2)S formation in endothelial cells and murine kidney. *Antioxidants*. 2022;12(1):66. doi:10.3390/antiox12010066
113. John A, Kundu S, Pushpakumar S, et al. GYY4137, a hydrogen sulfide donor modulates mir194-dependent collagen realignment in diabetic kidney. *Sci Rep*. 2017;7(1):10924. doi:10.1038/s41598-017-11256-3
114. Kundu S, Pushpakumar SB, Tyagi A, Coley D, Sen U. Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9. *Am J Physiol Endocrinol Metab*. 2013;304(12):E1365–78. doi:10.1152/ajpendo.00604.2012
115. Kundu S, Pushpakumar S, Khundmiri SJ, Sen U. Hydrogen sulfide mitigates hyperglycemic remodeling via liver kinase B1-adenosine monophosphate-activated protein kinase signaling. *Biochim Biophys Acta*. 2014;1843(12):2816–2826. doi:10.1016/j.bbamcr.2014.08.005
116. Wang G, Li W, Chen Q, Jiang Y, Lu X, Zhao X. Hydrogen sulfide accelerates wound healing in diabetic rats. *Int J Clin Exp Pathol*. 2015;8(5):5097–5104.
117. Mohammad G, Radhakrishnan R, Kowluru RA. Hydrogen sulfide: a potential therapeutic target in the development of diabetic retinopathy. *Invest Ophthalmol Vis Sci*. 2020;61(14):35. doi:10.1167/iops.61.14.35
118. Allen CL, Wolanska K, Malhi NK, et al. Hydrogen sulfide is a novel protector of the retinal glycocalyx and endothelial permeability barrier. *Front Cell Dev Biol*. 2021;9:724905. doi:10.3389/fcell.2021.724905
119. Shayea AMF, Renno WM, Qabazard B, Masocha W. Neuroprotective effects of a hydrogen sulfide donor in streptozotocin-induced diabetic rats. *Int J mol Sci*. 2023;24(23):16650. doi:10.3390/ijms242316650
120. Volpato GP, Searles R, Yu B, et al. Inhaled hydrogen sulfide: a rapidly reversible inhibitor of cardiac and metabolic function in the mouse. *Anesthesiology*. 2008;108(4):659–668. doi:10.1097/ALN.0b013e318167af0d
121. Faller S, Zimmermann KK, Strosing KM, et al. Inhaled hydrogen sulfide protects against lipopolysaccharide-induced acute lung injury in mice. *Med Gas Res*. 2012;2(1):26. doi:10.1186/2045-9912-2-26
122. Wei X, Zhang B, Zhang Y, et al. Hydrogen sulfide inhalation improves neurological outcome via NF-κB-mediated inflammatory pathway in a rat model of cardiac arrest and resuscitation. *Cell Physiol Biochem*. 2015;36(4):1527–1538. doi:10.1159/000430316
123. Wang YZ, Ngowi EE, Wang D, et al. The potential of hydrogen sulfide donors in treating cardiovascular diseases. *Int J mol Sci*. 2021;22(4).
124. True AL, Olive M, Boehm M, et al. Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. *Circ Res*. 2007;101(9):893–901. doi:10.1161/CIRCRESAHA.107.158998
125. Kang J, Li Z, Organ CL, et al. pH-controlled hydrogen sulfide release for myocardial ischemia-reperfusion injury. *J Am Chem Soc*. 2016;138(20):6336–6339. doi:10.1021/jacs.6b01373
126. Zhao Y, Yang C, Organ C, et al. Design, synthesis, and cardioprotective effects of N-mercapto-based hydrogen sulfide donors. *J Med Chem*. 2015;58(18):7501–7511. doi:10.1021/acs.jmedchem.5b01033
127. Bradley JM, Organ CL, Lefer DJ. Garlic-derived organic polysulfides and myocardial protection. *J Nutr*. 2016;146(2):403s–9s. doi:10.3945/jn.114.208066

## Diabetes, Metabolic Syndrome and Obesity

### Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>

**Dovepress**  
Taylor & Francis Group